Iterum Therapeutics plc (ITRM) Earnings History
Annual and quarterly earnings data from 2016 to 2024
Loading earnings history...
ITRM EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ITRM Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export ITRM earnings history in CSV or JSON format
Free sign-in required to download data
Iterum Therapeutics plc (ITRM) Earnings Overview
As of May 8, 2026, Iterum Therapeutics plc (ITRM) reported trailing twelve-month net income of -$27M, reflecting +57.4% year-over-year growth. The company earned $-0.59 per diluted share over the past four quarters.
Looking at the long-term picture, ITRM's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2016.
Iterum Therapeutics plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), NKTR (-$164M net income, -297.1% margin), SPRO (-$44M net income, -142.9% margin), ITRM has comparable earnings metrics. Compare ITRM vs PRAX →
ITRM Earnings vs Peers
Earnings metrics vs comparable public companies
ITRM Historical Earnings Data (2016–2024)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$25M | +35.4% | -$19M | $-1.26 | - | - |
| 2023 | -$38M | +13.6% | -$47M | $-2.96 | - | - |
| 2022 | -$44M | +51.5% | -$30M | $-3.63 | - | - |
| 2021 | -$92M | -76.1% | -$25M | $-8.41 | - | - |
| 2020 | -$52M | +49.6% | -$32M | $-32.49 | - | - |
| 2019 | -$103M | -33.8% | -$102M | $-7.10 | -278729.7% | -275732.4% |
| 2018 | -$77M | -162.0% | -$77M | $-98.32 | -8867.2% | -8810.0% |
| 2017 | -$29M | -118.4% | -$29M | $-58.08 | -5788.6% | -5798.2% |
| 2016 | -$13M | - | -$13M | $-26.59 | - | - |
See ITRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ITRM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ITRM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonITRM — Frequently Asked Questions
Quick answers to the most common questions about buying ITRM stock.
Is ITRM growing earnings?
ITRM EPS is $-0.59, with earnings growth accelerating to +57.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-27M.
What are ITRM's profit margins?
Iterum Therapeutics plc net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are ITRM's earnings?
ITRM earnings data spans 2016-2024. The accelerating earnings trend is +57.4% YoY. Historical data enables comparison across business cycles.